© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The curiosity around 3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol—known among chemists as a structural cousin to compounds like norepinephrine—sparked in the mid-20th century, right as synthetic organic chemistry took off. In university labs piecing together the puzzle of neurotransmitter analogs, researchers pushed boundaries to understand how modifications to natural scaffolds could influence both biological activity and industrial utility. People in the field often reflect on how intensive bench work, using now-classic amination and reduction methods, laid foundations for our knowledge about this class of compounds. Each generation of organic chemists stood on the previous one's shoulders, nudged further by improvements in purification, analytical methods, and a growing understanding of receptor interactions—years of effort were poured into teasing apart structure-activity relationships and wondering about new applications.
Most folks wouldn’t recognize 3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol unless they’ve spent time shuffling through glassware and shaking separatory funnels. As a fine solid or crystalline powder, it has a color that shifts from white to pale tan, especially if exposed to air and light. Solubility can surprise newcomers; strong polarity allows it to dissolve in water and alcohol, yet it resists mixing with non-polar solvents. It carries that distinct hint of phenolic sharpness—anyone who’s worked with catechol derivatives can confirm the unmistakable odor and the tendency for air to turn the compound a darker shade, a visual sign of oxidation at play. Melting points and exact densities often find themselves at the mercy of hydrogen bonding, which packs more punch than people realize, forcing chemists to dry samples thoroughly before running analysis.
Regulators and researchers often discuss how labeling can mean the difference between safety and chaos in handling such chemicals. Direct, clear hazard communication matters. Compounds like this one often require GHS pictograms and meticulous SDS documentation, spelling out their catechol nature, amine presence, and relevant emergency procedures. Ignoring these steps has burned more than a few lab hands and exposed many to inhalation or dermal risks. Shipping restrictions reflect a balance between utility and caution, sometimes frustrating those moving between academic and industrial settings. Labeling also rides on correct nomenclature—chemists know how easy it is to confuse this compound with similarly named analogs if care slips for just a moment.
Preparing this compound demands more than a paint-by-numbers approach. In practice, most lab routes start with 3,4-dihydroxybenzaldehyde. Reductive amination stands as a classic, harnessing methylamine and a selective reducing agent—sodium borohydride or catalytic hydrogenation, depending on the equipment at hand. Every step calls for clean technique: exclusion of oxygen, careful control of pH, and efficient extraction routines to separate the desired product from stubborn by-products. I’ve spent long hours optimizing these procedures, coaxing yields up and minimizing time spent under a fume hood. Many have stories of learning to handle exothermic additions and how column chromatography sometimes punishes carelessness. Down the line, purification can sneak up as a bottleneck, especially on scale-up, driving folks to tweak recrystallization or derivatization steps.
Reactive groups on this molecule invite both opportunity and headache. Phenolic hydroxyls open the door for etherification, esterification, and oxidation—each providing a fork in the road for generating analogs with tweaked potency or physical properties. Meanwhile, the methylamino moiety proves touchy, often forming salts for better handling or compatibility in multi-step syntheses. The compound also plays well in Mannich-type reactions, a favorite among medicinal chemists for introducing broader diversity. I recall late nights trialing protection strategies: benzyl ether for the catechols, sometimes a Boc group for the amino—each addition or removal shifting the compound’s workload in later steps. Focusing too much on one end of the molecule tends to reveal unexpected reactivity on the other, a reminder of chemical interconnectedness.
Navigating scientific literature gets tangled when this compound’s synonyms enter the mix. Some references turn up “3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol,” others use systematic IUPAC titles. In the pharma world, speculative trade names or abbreviations abound, with each research group clinging to its own shorthand. For those slogging through old patents or dusty volumes, recognizing local naming translates directly to success in pulling together comprehensive reviews or regulatory dossiers. Precise naming safeguards against miscommunication, especially with structurally similar analogs only a methyl or hydroxyl group away from this scaffold.
Handling this compound brings a set of hard-won lessons about personal safety. Catechol-based chemicals react quickly with oxygen, making storage under nitrogen or in amber vials a matter of daily routine, not just good practice. Personal protective equipment isn’t optional: gloves, eye protection, and lab coats shield against both acute and chronic exposure. Proper ventilation and fume hoods handle volatile by-products or accidental splashes. There’s also a shared wisdom about never ignoring minor spills—overexposure takes a toll on skin or lungs, and the compound’s staining power means mistakes linger as visual reminders. Disposal protocols reflect a respect for both personal and environmental health, underlining how mistakes have consequences that can echo far from the bench.
Research interest in this compound naturally travels to neuromodulator pathways, psychiatric pharmaceuticals, and biochemical signaling studies. Analogs of 3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol map onto key neurotransmitter backbones, drawing attention for antidepressant, antihypertensive, and central nervous system roles. Beyond pharmaceuticals, it’s earned a spot in developing sensors, polymer additives, or analytical standards. Academic groups benefit from its use as a starting scaffold for more elaborate molecules, while industry labs chase both incremental and breakthrough advances. These efforts rest on the compound’s reactivity, laying groundwork for future modifications and discovery projects.
Every research cycle breathes new questions into an old compound. Scientists keep pressing on, asking how small modifications could improve selectivity or cut toxicity. Recent years have seen more money and energy funneled into receptor agonism, fine-tuning binding affinities, or generating new prodrugs that release active agents. High-throughput experimentation, spectral characterization, and data sharing push progress further, inviting multidisciplinary teams to take part. More young chemists learn alongside experienced mentors, transferring tricks and sharing failed syntheses—not every experiment hits the bullseye, but transparency in methods ensures learning sticks. Digital tools and machine learning pick up some repetition, offering fresh predictions for analogs and unexplored scaffolds connected to the compound.
Every promising molecule carries dual faces—therapeutic potential and risk. Researchers scrutinize possible cytotoxicity, cardiovascular impact, and metabolic fate. Catechol groups tend to undergo rapid oxidation, leading to the generation of reactive quinones that can turn cytotoxic or mutagenic, especially in high concentrations or prolonged exposures. I’ve listened to toxicologists talk about glutathione depletion, oxidative stress, and how animal studies often sound alarms overlooked until later clinical stages. Current research leans hard into dose dependence, route of administration, and metabolic byproduct tracking. Nothing in toxicology feels static; emerging data or new regulatory guidance can change acceptable usage in a heartbeat, making vigilance and lifelong learning a must for anyone working with this class of chemicals.
As development continues, researchers and industry partners eye both the expanding opportunities and stubborn barriers surrounding 3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol. Emerging technologies promise better targeting or environmentally conscious synthesis, but the lessons learned from decades spent balancing innovation with safety remain as relevant as ever. Investment in automation, green chemistry, and data-driven prediction will likely shift how we interact with not just this molecule, but with entire classes of biologically active chemicals. Even so, deep expertise, common sense handling, and firsthand experience provide the foundation needed to weather new regulatory or scientific changes. The compound’s journey offers both a snapshot of chemical progress and a reminder that discovery’s road always stretches further for those willing to keep questioning.
3,4-Dihydroxy-Α-((Methylamino)Methyl)Benzyl Alcohol isn’t a name that comes up in casual conversation, but its reach stretches into everyday life. In the lab, this compound is better known as noradrenaline or norepinephrine. This one molecule tells a big story, from hospital emergency rooms to pharmaceutical laboratories, and even the foundation of our understanding of stress and alertness.
Anyone who’s spent time watching real doctors in action during a crisis has seen how quickly the right medicine can change outcomes. Noradrenaline steps in as a first-choice drug to raise dangerously low blood pressure. Whenever someone faces septic shock—a condition that can leave the body’s organs starved of blood—medics turn to noradrenaline for its power to tighten up blood vessels and push up pressure. Years ago, people used drugs like dopamine more often, but study after study kept showing that noradrenaline works with fewer complications. Large trials in the medical journals say it saves more lives and reduces the risk of irregular heartbeats. With critical care reaching more patients every year, having a reliable drug like this changes the odds for those in life-threatening situations.
On another front, noradrenaline draws heavy attention in neuroscience and psychiatry. Anyone who’s dealt with depression or anxiety hears plenty about brain chemistry, but real science ties this compound straight to the feeling of alertness and motivation. Studies published in journals like Nature show how imbalances can link to conditions like depression and ADHD. Pharmaceuticals designed to nudge noradrenaline levels—think SNRIs—play a key role in treating these mental health challenges. It’s not just speculation; data over several decades chart real improvements for patients when these pathways get the right boost.
Labs working on everything from Alzheimer’s disease to new antidepressants use noradrenaline as a reference point in experiments. Measuring its levels in blood or brain tissue reveals clues to underlying illness. Research funding keeps flowing into projects that map out exactly how this chemistry links to memory, attention, response to stress, and long-term brain health. The more scientists dig in, the more they realize how noradrenaline shapes responses far beyond a shot of adrenaline in a tense moment.
No drug works without a downside. In the emergency room, too much noradrenaline can lead to problems like high blood pressure, arrhythmias, or damage to fingers and toes because of over-tightened vessels. That’s why medical teams stay vigilant, adjusting doses and monitoring heart rhythms. Some are looking at new delivery methods or related compounds to give all the benefits with fewer risks. In mental health, the challenge stays with predicting individual response—something genetics research is starting to tackle. The best solutions come when hospitals, labs, and drug makers swap data and put patient experience at the center of any decision. With more transparency and real-world testing, this old standby can keep saving lives and improving daily well-being for a long time to come.
I’ve met folks who rush out to buy the latest product after seeing an ad, only to get surprised by how their body reacts weeks later. I’ve done the same, eager for a fix, caught off guard by itching, dizziness, or stomach trouble nobody warned me about. Reading the tiny print on packaging can feel like trying to decode a secret message, but you shouldn't need a pharmacy degree to know what could happen.
Take over-the-counter pain relievers. They promise quick relief, but they can also introduce headaches, rashes, or stomach pain if someone takes them a lot. Too much acetaminophen, for example, puts easy strain on the liver. That isn’t a scare tactic. According to the FDA, thousands of ER visits come from regular folks using ordinary painkillers the same way they brush their teeth: day in, day out, rarely thinking twice. Anyone who’s watched a parent or friend fight through complications knows this feels a lot more real than the clinical warnings on a bottle.
Some reactions don’t appear for days or weeks. Skin creams containing steroids, for example, leave skin thin with steady use, even if someone starts out feeling great. I knew a neighbor who found relief from a rash, but months later couldn’t figure out why their skin bruised so easily. It turned out the cream quietly took a toll over time. It’s easy to trust something that helps in the short term, but slow-building effects slip under the radar for people in pain or just chasing results.
Dietary supplements and herbal blends get a pass in a lot of circles because they're sold “naturally.” That label doesn't mean risk-free. Green tea extract, sold for weight loss, can land someone in the hospital with liver damage if they use too much. Melatonin, pitched as a simple sleep aid, leaves some users groggy, nauseous, or wired the next day. It’s easy to forget supplements aren’t just vitamins and sunshine in a bottle; they can hit the body hard if people pile them on without a second thought.
The way forward demands straightforward talk—something everyone, including doctors and marketers, needs to get better at. Nobody gains from hiding facts or softening the truth. Honest labels written in plain language would make a difference. I’ve found pharmacists willing to stop and spell out possible reactions clear as day, and that’s helped friends and family avoid serious mix-ups. Pharmaceutical companies can share post-market data more openly, and online forums give real-world stories that go beyond the back of the box.
Personal vigilance also counts. I’ve learned to read ingredients before swiping a debit card. Telling doctors about every supplement or medication—down to the herbal tea I sometimes drink—has headed off interactions more than once. People talk plenty about empowerment these days, but clear, direct information still means the most. At its core, that’s where better decisions begin.
I’ve seen plenty of labs take shortcuts with storage, especially with lesser-known chemicals that don’t make splashy headlines. It’s easy to assume storage is just about meeting a checklist, but slips here can ripple into bigger problems—health risks, failed research, or even regulatory headaches. I’ve worked with multiple research teams juggling many reagents, and proper storage of complex organics stands out as a quiet cornerstone of safe and successful science.
This compound lands in a tricky spot. It blends the reactive features of catechols with a secondary amine. Catechols, with their two hydroxyls lounging on the aromatic ring, don’t take kindly to open air and light. Oxygen and moisture tend to oxidize them, turning the compound brown or black, sometimes gumming up instruments or skewing experiments. From my bench experience, solutions turn especially fast—sometimes overnight, sometimes within hours—if left unprotected.
The methylamino group opens another set of storage demands. Amines can pull water from the air, which can dilute or degrade the sample and even corrode containers over time. I’ve seen labels peeled off by condensation alone.
It’s easy to say “just keep it cool and dry,” but there’s a big difference between textbook advice and daily handling. I’ve learned through trial and error, and from watching senior colleagues, that it’s the little steps that make all the difference:
These choices aren’t just a personal preference; labs and companies carry regulatory obligations under guidelines like OSHA or the European CLP. From my own training, each step in storage aligns with documented incidents and published stability studies. For folks handling these chemicals at home or in startups, don’t forget Material Safety Data Sheets—they’re a goldmine for confirming the basics that keep everyone out of trouble.
Experience tells me one last thing: the best storage systems grow out of good habits. Quarterly inventory audits, spot checks for degraded samples, and direct communication across research teams built confidence and cut down waste. Spilled bottles and ruined reagents became the rare exception instead of the weekly routine. Setting up a storage protocol isn’t glamorous, but every safe, effective experiment grows from these choices. That’s something any science team can get behind.
Walking down the pharmacy aisle or browsing an online drugstore can leave folks scratching their heads about which items need a doctor's note. This question pops up often — "Do I need a prescription for this?" The answer shapes a lot: how easy it is to get the product, the cost, who watches out for safety, and even how well the item works.
Every time I’ve picked up antibiotics or blood pressure medicine, I’ve needed a prescription. That rule serves a purpose. Prescription rules help keep dangerous drugs out of the wrong hands. This matters because serious side effects, mixing with other medicines, or simply taking the wrong dose can spell trouble. Medications like opioid painkillers or antidepressants have risks that don’t always show up in the headlines but hit home in emergency rooms across the country. Prescription oversight helps doctors catch problems early and guide people to safer choices.
Not everything calls for a trip to see the doctor. Medications like paracetamol, ibuprofen, or allergy pills sit on store shelves for a reason. The scientific community and regulators have looked at how people use these drugs and found that, with instructions on the label, most folks handle them well. I often reach for ibuprofen after a long bike ride and never have to ask for a prescription — that’s because people typically use it safely and rarely run into dangerous issues at standard doses.
Products like certain acne creams, allergy medications, or devices like inhalers can be harder to figure out. In the past, some of these needed a prescription due to risks — but advances in research have shown that many can be safely managed with the right information on the packaging. Take epinephrine auto-injectors: Many states in the U.S. now let pharmacists provide them without a prescription, especially for schools. That shift came from public health campaigns that focused on quick access during emergencies.
Getting the balance right between easy access and safety shapes a lot of lives. Requiring a prescription sometimes keeps costs higher or makes simple health fixes harder to get. On the other hand, not having barriers can lead to misuse. The Centers for Disease Control and Prevention reported thousands of yearly hospitalizations linked to unapproved or misused medications that started as over-the-counter.
Pharmacies and regulators can do better by offering more clear labeling, stronger pharmacist advice, and updated online resources. It helps when clients can check a reliable website or talk to a pharmacist, rather than combing through forums or guessing. Some countries use digital prescriptions and real-time pharmacist consultations to both control access and educate customers. This model lines up with the move toward personalized care, where each shopper gets advice that fits their medical history and needs.
The question of whether a prescription is needed deserves thoughtful answers. Regulators, pharmacies, and doctors share a responsibility to keep things safe and accessible. People deserve clear facts and fair access — and with the right approach, both are possible.
Every pill, vitamin, or supplement in your medicine cabinet comes with one big question: how much should go into your body? The answer carries real weight. Even an otherwise harmless vitamin can turn risky in excessive amounts. Take something as basic as acetaminophen, the comfort for a headache. Used as directed, it can nip pain in the bud. Too much, though, can put intense strain on your liver. I remember a friend in college who ignored the dose instructions for cold medicine and wound up feeling much worse, all because he figured more was better.
Manufacturers invest time and testing to recommend the right dose. Regulatory agencies like the FDA dive deeply into trial data before approving labels. These numbers reflect what’s safe—what’s backed up by results from real people during studies, not just estimates or educated guesses. Harvard Health points out that even simple over-the-counter drugs can carry clear risks above their suggested amounts. Overdoses send hundreds of thousands to emergency rooms in the United States each year, much of it stemming from what seemed like harmless extra tablets.
The right amount isn’t always one-size-fits-all. Age, weight, genetics, and underlying health shape what’s safe. Kids need less—sometimes much less—than adults. Older adults process substances more slowly. Some drugs interact with foods, alcohol, or other medicines. Grapefruit juice, for example, can make cholesterol medicines build up in the body to dangerous levels. These differences remind us that “recommended” means recommended for most people, not everyone.
Most of us want quick relief, so there’s a temptation to double up on doses or take medication more often. A few years ago, while recovering from wisdom tooth surgery, stubborn pain tempted me to juggle painkillers and anti-inflammatories. My dentist urged caution and explained that mixing pain medications can spiral into gastrointestinal problems or worse. That lesson stuck: follow the dosages, document what gets taken and when, and check with a doctor before mixing.
Safe dosage starts with clear information. Always check the instructions or ask a pharmacist—guesswork is risky. A pill organizer helps avoid double doses, especially when routines get busy. If unclear instructions or faded labels cause confusion, reaching out to a healthcare provider for clarification fixes more than just peace of mind. Keeping a list of current medications on your fridge, especially if you see multiple specialists, heads off dangerous drug interactions.
Digital health tools already help some folks keep their doses straight. Apps send reminders, track intake, and flag possible interactions. Healthcare needs honest conversations about actual habits, not just ideal routines. Doctors benefit from patients telling the whole truth about what and how much they take. At the same time, packaging and labels deserve clearer instructions—and larger print. Community programs can help those who struggle with literacy or language barriers get the message about safe dosing. In the end, knowing and respecting recommended amounts protects not just individuals but families and communities.
| Names | |
| Preferred IUPAC name | 4-(Hydroxymethyl)-2-(methylaminomethyl)benzene-1,3-diol |
| Other names |
Norepinephrine Noradrenaline Levarterenol Arterenol |
| Pronunciation | /ˌθriˌfaɪv.daɪˈhaɪ.drɒksiˌæl.fəˌmɛθ.ɪl.əˈmiː.noʊˌmɛθ.ɪlˈbɛn.zɪl ˈæl.kə.hɒl/ |
| Identifiers | |
| CAS Number | 13397-45-6 |
| 3D model (JSmol) | `/data/structures/jmol/2/3D/Dihydroxy-Alpha-MethylaminoMethylBenzylAlcohol.jmol` |
| Beilstein Reference | 1576781 |
| ChEBI | CHEBI:132709 |
| ChEMBL | CHEMBL71177 |
| ChemSpider | 21710116 |
| DrugBank | DB01488 |
| ECHA InfoCard | 05e90eaf-0e52-48ae-ab99-cd01915c1042 |
| EC Number | 1.1.1.28 |
| Gmelin Reference | 1131734 |
| KEGG | C05652 |
| MeSH | D06.472.699.586.260 |
| PubChem CID | 151129 |
| RTECS number | SL8575000 |
| UNII | HW6SY82LRL |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C9H13NO3 |
| Molar mass | 169.194 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.264 g/cm3 |
| Solubility in water | soluble |
| log P | 0.00 |
| Vapor pressure | 5.55E-7 mmHg at 25°C |
| Acidity (pKa) | 9.13 |
| Basicity (pKb) | 9.47 |
| Magnetic susceptibility (χ) | -78.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.625 |
| Viscosity | Viscous oil |
| Dipole moment | 3.15 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 189.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -180.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -1849 kJ/mol |
| Pharmacology | |
| ATC code | R03CC02 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P264, P270, P280, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | 110°C |
| Lethal dose or concentration | LD50 oral rat 1700mg/kg |
| LD50 (median dose) | 1680 mg/kg (rat, oral) |
| NIOSH | UR7270000 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for 3,4-Dihydroxy-Α-((Methylamino)Methyl)Benzyl Alcohol is not specifically established by OSHA or NIOSH. |
| REL (Recommended) | 3,4-Dihydroxy-Α-((Methylamino)Methyl)Benzyl Alcohol: 5 mg/m³ |
| Related compounds | |
| Related compounds |
Methyldopa L-DOPA Dopamine Norepinephrine Epinephrine Methylnorepinephrine Phenylalanine Tyrosine |
